RPC: Moxifloxacin Hydrochloride Eye Drops have obtained a drug registration certificate

RPC announced that its subsidiary Jiangxi Shining Pharmaceutical Co., Ltd. has obtained the Drug Registration Certificate for Moxifloxacin Hydrochloride Eye Drops issued by the National Medical Products Administration. This medication is used to treat bacterial conjunctivitis caused by sensitive microorganisms and has been included in the Category B drug list of the medical insurance catalog, marking its successful completion of the consistency evaluation for generic drugs

According to the Zhitong Finance APP, RPC (000650.SZ) announced that its subsidiary Jiangxi Shining Pharmaceutical Co., Ltd. recently received the drug registration certificate for Moxifloxacin Hydrochloride Eye Drops approved and issued by the National Medical Products Administration.

Moxifloxacin Hydrochloride Eye Drops are clinically used for the treatment of bacterial conjunctivitis caused by sensitive microorganisms (including: Gram-positive bacteria, Gram-negative bacteria, Chlamydia trachomatis, etc.) and are classified as Category B drugs in the medical insurance catalog. This Moxifloxacin Hydrochloride Eye Drops has been approved for marketing as a Class 4 chemical drug, marking that this product is considered to have passed the consistency evaluation of generic drugs